Mike Collins, PhD (he/him/his)

Senior Scientist, Translational Research
Foghorn Therapeutics

I am a senior scientist in the Translational Research group at Foghorn Therapeutics. I serve as translational lead for FHD-609, as well as supporting other clinical and pre-clinical programs focused in the area of chromatin regulation in cancer. Prior to Foghorn, I had research positions at Astrazeneca and Brigham and Women's/Dana Farber Cancer Institute. I obtained my PhD in Cell, Molecular and Developmental Biology from Tufts University.

Poster(s):

• (P 271) PHARMACODYNAMICS AND MECHANISTIC IMPACTS OF FHD-609, A BROMODOMAIN-CONTAINING PROTEIN 9 DEGRADER, IN A PHASE 1 STUDY IN PATIENTS WITH ADVANCED SYNOVIAL SARCOMA OR SMARCB1-LOSS TUMORS